In this episode, we present the second part of our conversation with the authors of the scouting reports for the teams in the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational.  Plus, we highlight Q&As from theMednet.org about the T'd Up T-Cells teams AND record an interview with Dr. Bill St. Clair, the first author of the phase 2 dazodalibep study.  It's a long episode because there's so much content!

Links to the Q&As from theMednet.org discussed in this episode:

• What is your approach to managing sicca symptoms in patients not responding or not tolerating conservative measures, pilocarpine, and cevimeline?
• What is your approach to immunomodulatory treatment in patients with Sjogren’s syndrome who have active serologies (i.e. elevated ESR, hypergammaglobulinemia, hypocomplementemia) but minimal symptoms?
• What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
• What factors drive you to prioritize T vs B cell inhibition when choosing therapies for patients with refractory SLE?

To learn more about RheumMadness:
https://sites.duke.edu/rheummadness/

Subscribe to our newsletter:
https://lists.duke.edu/sympa/subscribe/rheummadness

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/